Tolvaptan regulatory update

Otsuka submitted an NDA to Japan's Pharmaceutical and Medical Devices Agency for tolvaptan to treat autosomal dominant polycystic kidney disease (ADPKD). The vasopressin 2 (V2) receptor antagonist ha...